A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Planned End Date changed from 28 Feb 2021 to 28 Dec 2021.
- 05 Dec 2017 Status changed from not yet recruiting to recruiting.